{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigbkdf7oaaoyplo4jqfzbm3yeg73zlnk4e2jsv43u4tilymb6obwm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mmqonmzv24c2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaoiwlof2cu6cserm2ksy765vc5yo2dxdigvse2vtwpf5p2txazhq"
    },
    "mimeType": "image/jpeg",
    "size": 150141
  },
  "path": "/2026/05/26/ai-biotech-bighat-biosciences-ceo-on-ai-drug-development-hype/?utm_campaign=rss",
  "publishedAt": "2026-05-26T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Artificial intelligence",
    "biotechnology",
    "health tech",
    "STAT+"
  ],
  "textContent": "CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.",
  "title": "STAT+: An AI biotech CEO sets the record straight on AI drug development hype",
  "updatedAt": "2026-05-22T17:33:30.000Z"
}